Patents by Inventor Piet BRUIJNZEEL

Piet BRUIJNZEEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
    Patent number: 11844823
    Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: December 19, 2023
    Assignee: POLYPHOR AG
    Inventors: Christian Ludin, Manfred Keller, Piet Bruijnzeel, Johann Zimmermann, Philip Barth, Eric Chevalier
  • Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
    Patent number: 11235024
    Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 1, 2022
    Assignee: POLYPHOR AG
    Inventors: Christian Ludin, Manfred Keller, Piet Bruijnzeel, Johann Zimmermann, Philip Barth, Eric Chevalier
  • BETA-HAIRPIN PEPTIDOMIMETIC WITH ELASTASE INHIBITORY ACTIVITY AND AEROSOL DOSAGE FORMS THEREOF
    Publication number: 20220023379
    Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
    Applicant: POLYPHOR AG
    Inventors: Christian LUDIN, Manfred KELLER, Piet BRUIJNZEEL, Johann ZIMMERMANN, Philip BARTH, Eric CHEVALIER
  • BETA-HAIRPIN PEPTIDOMIMETIC WITH ELASTASE INHIBITORY ACTIVITY AND AEROSOL DOSAGE FORMS THEREOF
    Publication number: 20200230203
    Abstract: The present invention relates to pharmaceutical aerosols comprising a ?-hairpin peptidomimetic of formula cyclo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), or a pharmaceutically acceptable salt thereof, having inhibitory activity against human neutrophil elastase. It further relates to solid or liquid pharmaceutical compositions and kits for preparing and administering such aerosols. The invention can be used for the prevention, management or treatment of pulmonary diseases, such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis (CF), non-cystic fibrosis bronchiactasis (NCFB), or chronic obstructive pulmonary disease (COPD), or infections, or diseases, or conditions of the lungs, being mediated by or resulting from human neutrophil elastase activity.
    Type: Application
    Filed: May 31, 2017
    Publication date: July 23, 2020
    Applicant: POLYPHOR AG
    Inventors: Christian LUDIN, Manfred KELLER, Piet BRUIJNZEEL, Johann ZIMMERMANN, Philip BARTH, Eric CHEVALIER